PHARMACOKINETICS OF A NEWLY FORMULATED IBUPROFEN TABLET IN ARABIC HEALTHY INDIVIDUALS

DUAA JAAFAR JABER AL-TAMIMI; SABA ABDULHADI JABER; HALAH TALAL SULAIMAN

doi:10.22159/ijap.2025v17i5.55640

Authors

DUAA JAAFAR JABER AL-TAMIMI College of Pharmacy, Al-Nisour University, Ministry of Higher Education and Scientific Research, Baghdad, Iraq
SABA ABDULHADI JABER Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Baghdad, Iraq
HALAH TALAL SULAIMAN Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Baghdad, Iraq

DOI:

https://doi.org/10.22159/ijap.2025v17i5.55640

Keywords:

Ibuprofen tablet, Pharmacokinetics, Arabic men

Abstract

Objective: To evaluate the pharmacokinetics (PKs) of a newly formulated immediate-release ibuprofen (IBU) 400 mg tablet administered to healthy Arabic volunteers.

Methods: This was a single-dose study conducted on healthy Arabic subjects under overnight fasting. Each subject received one 400 mg tablet of the newly formulated IBU. Blood samples were collected at pre-determined intervals for up to 12 h post-dose. Pharmacokinetic parameters including maximum plasma concentration (Cmax), time to reach maximum concentration (Tmax), area under the curve from time zero to last measurable concentration (AUC₀₋ₜ), area under the curve from time zero to infinity (AUC₀₋∞), elimination rate constant (Kₑ), elimination half-life (T 0.5), mean residence time (MRT), clearance/bioavailability (Cl/F), and volume of distribution/bioavailability (Vd/F) were calculated using non-compartmental analysis.

Results: The mean±SD pharmacokinetic parameters of IBU after a single 400 mg dose were as follows: Cmax = 26.1±4.7 µg/ml, Tmax = 1.98±0.56 h, AUC₀₋ₜ = 103.4±23.5 µg·h/ml, AUC₀₋∞ = 107.8±28.6 µg·h/ml, %AUCextra= 3.5±2.6, Kₑ = 0.310±0.047 h⁻¹, T 0.5 = 2.29±0.42 h, MRT = 4.17±0.84 h, Cl/F = 3.9±0.71 l/h, Vd/F = 12.6±2.3 l. The newly formulated IBU tablet was well tolerated by all participants with no significant adverse effects observed.

Conclusion: The present investigation introduced the PK parameters of a newly formulated IBU tablet administered to Arabic healthy individuals which were found to be comparable to the data presented in literature for other IBU tablets. Consequently, the new IBU formula can be introduced to the market as a safe and effective product.

References

1. Rainsford KD. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009;17(6):275-342. doi: 10.1007/s10787-009-0016-x, PMID 19949916.

2. Al-Dalaen SMI, Hamad AW, AL-Hujran TA, Al-Btoush HA, Al-Halaseh L, Magharbeh MK. Bioavailability and bioequivalence of two oral single dose of ibuprofen 400 mg to healthy volunteers. Biomed Pharmacol J. 2021;14(1):435-44. doi: 10.13005/bpj/2143.

3. Dongseong S, Sook JL, Yu-Mi H, Young Sim C, Jae Won K, Se Rin P. Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen. Drug Des Dev Ther. 2017;4(11):135-41.

4. Mendes GD, Mendes FD, Domingues CC, de Oliveira RA, da Silva MA, Chen LS. Comparative bioavailability of three ibuprofen formulations in healthy human volunteers. Int J Clin Pharmacol Ther. 2008 June;46(6):309-18. doi: 10.5414/cpp46309, PMID 18541128.

5. Schettler T, Paris S, Pellett M, Kidner S, Wilkinson D. Comparative pharmacokinetics of two fast-dissolving oral ibuprofen formulations and a regular-release ibuprofen tablet in healthy volunteers. Clin Drug Investig. 2001;21(1):73-8. doi: 10.2165/00044011-200121010-00010.

6. Moore RA, Derry S, Wiffen PJ, Straube S. Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs-a systematic review. Br J Clin Pharmacol. 2015;80(3):381-8. doi: 10.1111/bcp.12628, PMID 25784216.

7. Heintze K, Fuchs W. Effects of food on pharmacokinetics of immediate release oral formulations. Br J Clin Pharmacol. 2015;80(5):1239. doi: 10.1111/bcp.12712, PMID 26140311.

8. Weiser T, Schepers C, Mück T, Lange R. Pharmacokinetic properties of ibuprofen (IBU) from the fixed-dose combination IBU/caffeine (400/100 mg; FDC) in comparison with 400 mg IBU as acid or lysinate under fasted and fed conditions-data from 2 single-center, single-dose, randomized crossover studies in healthy volunteers. Clin Pharmacol Drug Dev. 2019 August;8(6):742-53. doi: 10.1002/cpdd.672, PMID 30897305.

9. Al-Tamimi DJ, Hussien AA. Formulation and characterization of self-microemulsifying drug delivery system of tacrolimus. Iraqi J Pharm Sci. 2021;30(1):91-100. doi: 10.31351/vol30iss1pp91-100.

10. Jadhav SV, Nikam AS, Gunjal SB. To study the regulatory guidelines for API of ibuprofen: a review. Asian J Pharm Res Dev. 2024;12(1):98-106. doi: 10.22270/ajprd.v12i1.1356.

11. Das Purkayastha HD, Nath B. Formulation and evaluation of oral fast disintegrating tablet of ibuprofen using two super disintegrants. Int J Curr Pharm Sci. 2017;9(4):92-5. doi: 10.22159/20966.

12. Devi JR, Das B. Preparation and evaluation of ibuprofen effervescent granules. Asian J Pharm Clin Res. 2019 Aug 7;12(8):52-5.

13. Tiwari A, Gabhe SY, Mahadik KR. Comparative study on the pharmacokinetics of ibuprofen alone or in combination with piperine and its synthetic derivatives as potential bioenhancer. Int J Pharm Sci Res. 2020;12(1):363-71.

14. Alani ME, Al-Tamimi DJ, Al-Mahroos MI. Ammoo1 AM, al-Tamim MJ, Ibraheem JJ. Bioequivalence study of a newly developed azithromycin suspension versus Zithromax® following a single dose to healthy fasting adult subjects. IJDD. 2021;11(1):159-65.

15. Al-Tamimi DJ, Alani ME. Ammoo AM. Ibraheem JJ. Linear pharmacokinetics of doxazosin in healthy subjects. Int J Res Pharm Sci. 2020;11(1):1031-9.

16. Jabbar EG, Al-Tamimi DJ, Al-Mahroos MI, Al-Tamimi ZJ, Ibraheem JJ. Pharmacokinetics and bioequivalence study of two formulations of cefixime Suspension ‎. J Adv Pharm Educ Res. 2021;11(1):170-7. doi: 10.51847/LstEumAkic.

17. Al-Mahroos MI, Al-Tamimi DJ, Al-Tamimi ZJ, Ibraheem JJ. Clinical pharmacokinetics and bioavailability study between generic and branded fluconazole capsules. J Adv Pharm Educ Res. 2021;11(1):161-9. doi: 10.51847/UePrHyehg4.

18. Ammoo AM, Al-Tamimi DJ, Al-Mahroos MI, Al-Tamimi MJ, Ibraheem JJ. Pharmacokinetics of fluconazole tablets administered to healthy volunteers. J Adv Pharm Edu Res (JAPER). 2021;11(2):93.

19. Al-Tamimi DJ, Maraie NK, Arafat T. Comparative bioavailability (bioequivalence) study for fixed dose combination tablet containing amlodipine, valsartan and hydrochlorothiazide using a newly developed HPLC-MS/MS method. Int J Pharm Sci. 2016;8(7):296-305.

20. Al-Tamimi D, Al-Kinani K, Taher S, Hussein A. Effect of food on the pharmacokinetics of fluoxetine in healthy male adult volunteers. Iraqi J Pharm Sci. 2023;31Suppl:153-61. doi: 10.31351/vol31issSuppl.pp153-161.

21. Jaber Al-Tamimi DJJ, Abbas Al-Mahroos MI, Jaber Al-Tamimi MJ, Jaber Ibraheem J. Pharmacokinetic comparison and bioequivalence evaluation between a newly formulated generic and the brand cefuroxime axetil tablets in healthy male adult fasting subjects. Res J Pharm Technol. 2022;15(5):2184-92. doi: 10.52711/0974-360X.2022.00363.

22. Al-Tamimi DJJ. Review article ophthalmic dosage forms. Kerbala J Pharm Sci. 2020;18:81-202.

23. Moore AR, Derry S, Straube S, Ireson Paine J, Wiffen PJ. Faster, higher, stronger? Evidence for formulation and efficacy for ibuprofen in acute pain. Pain. 2014;155(1):14-21. doi: 10.1016/j.pain.2013.08.013, PMID 23969325.

24. International council for harmonization of technical requirements for pharmaceuticals for human use (ICH), ICH harmonized guidance: guidance for good. Clin Pract. 2016 Nov;E6:(R2).

25. E6 (R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1). Guidance for industry. Center for drug evaluation and research (CDER), Center for Biologics Evaluation and Research (CBER), March: United States Department of Health and Human Services, Food and Drug Administration; 2018.

26. WMA Declaration of Helsinki, ethical principles for medical research involving human subjects, 64th WMA general assembly. Fortaleza, Brazil; 2013.

27. Farrar H, Letzig L, Gill M. Validation of a liquid chromatographic method for the determination of ibuprofen in human plasma. Journal of Chromatography B. 2002;780(2):341-8. doi: 10.1016/S1570-0232(02)00543-3.

28. Canaparo R, Muntoni E, Zara GP, Della Pepa C, Berno E, Costa MS. Determination of ibuprofen in human plasma by high-performance liquid chromatography: validation and application in pharmacokinetic study. Biomed Chromatogr. 2000;14(4):219-26. doi: 10.1002/1099-0801(200006)14:4<219::AID-BMC969>3.0.CO;2-Z, PMID 10861732.

29. Ganesan M, Rauthan S, Pandey Y, Tripathi P. Determination of ibuprofen in human plasma with minimal sample pretreatment. Int J Pharm Sci Res. 2010;1(5):120-7. doi: 10.13040/IJPSR.0975-8232.1(5).120-27.

30. Bioanalytical method validation guidance for industry. United States department of health and human services, food and drug administration, center for drug evaluation and research (CDER), Center for Veterinary Medicine (CVM); May 2018.

31. Leon S, Andrew BC. Murray D. Shargel and Yu’s applied biopharmaceutics and pharmacokinetics. 8th ed. New York: McGraw-Hill Education/Medical; 2021.

32. Hartmut D, Stephan S. Rowland and Tozer’s clinical pharmacokinetics and pharmacodynamics: concepts and applications. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2019.

33. Schober P, Vetter TR. Nonparametric statistical methods in medical research. Anesth Analg. 2020;131(6):1862-3. doi: 10.1213/ANE.0000000000005101.